Tradestie Institutional Equity Comparison Engine

ABTS vs ATHA โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

ATHA Overall Edge

ATHA Captures Institutional Edge (2โ€“0 Pillars ยท 6โ€“2 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Athira Pharma, Inc. Common Stock (ATHA) driven by superior Growth & Margin, Momentum & Technical. Fundamentally, ABTS trades at N/M Forward P/E with -46.3% operating margin (-20.0% YoY revenue) versus ATHA at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, ABTS sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against ATHA sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
ABTS N/M vs ATHA N/M Fwd P/E
Growth & Margin Winner ATHA
Op Margin -46.3% vs 0.0% ยท YoY -20.0% vs +0.0%
Momentum & Technical Winner ATHA
1Y -95.1% vs +12.5% ยท 52W Pos 0% vs 80%
Options & Structure Winner Tie
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (N/A IV)
ABTS NASDAQ
Abits Group Inc Ordinary Shares
Finance Services
$0.31
-6.33% 1D
Market Cap $1.1M
1M Return -73.64%
1Y Return -95.1%
Forward P/E N/M
Unified AI Score
50.5 / 100 HOLD
Tech 50.0 Fund 55.0 Flow 50.0 Mom 59.0
ATHA NASDAQ
Athira Pharma, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$6.75
-6.12% 1D
Market Cap $26.6M
1M Return +73.75%
1Y Return +12.5%
Forward P/E N/M
Unified AI Score
56.2 / 100 HOLD
Tech 55.0 Fund 52.0 Flow 50.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: ABTS -95.1% ATHA +12.5% Spread: +52.44 pp (ATHA Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
ABTS TTM Op. Margin: -46.3% ATHA TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ABTS vs ATHA. Trailing 12-month operating profitability (ABTS -46.3% vs ATHA 0.0%) and valuation multiples (ABTS N/M vs ATHA N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: ABTS (2) vs ATHA (6)
Institutional Metric ABTS ATHA Criterion Row Winner
Market Capitalization Scale $1.1M $26.6M Larger Scale ATHA
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth -20.0% +0.0% Higher Growth ATHA
Operating Margin (TTM) Profitability -46.3% 0.0% Higher Margin ATHA
Net Profit Margin Profitability -60.8% 0.0% Higher Margin ATHA
Return on Equity (ROE) Capital Efficiency -60.0% -89.4% Higher ROE ABTS
52-Week Range Position Momentum 0% ($0โ€“$7) 80% ($0โ€“$8) Stronger Trend ATHA
Beta / 30D Volatility Risk Regime 1.70ฮฒ ยท 224% Vol 6.17ฮฒ ยท 241% Vol Lower Realized Risk ABTS
Unified Institutional Score Composite Signal 50.5 / 100 (HOLD) 56.2 / 100 (HOLD) Higher Composite ATHA

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full ABTS vs ATHA Buy Guide
ABTS UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live ABTS Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
ATHA UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live ATHA Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither ABTS nor ATHA registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.